Educating for integration

Robinson, Nicola; Liu, Jianping; Sarsina, Paolo Roberti di; Haramati, Aviad

doi:10.1016/j.eujim.2013.12.018

Cited by 2 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the term integrative medicine (IM) has been used frequently in different healthcare settings, there is not a standard definition for it [103]. In China, IM refers to the integration of TCM modality and conventional medicine modality as TCM is usually practiced alongside with conventional medicine especially in hospital settings [104]. This is of particular importance for complex diseases which may not be addressed by one medical system alone.…”

Section: Priority Area 8: Evaluating the Value Of Integrative Medicinmentioning

confidence: 99%

Applying regulatory science in traditional chinese medicines for improving public safety and facilitating innovation in China: a scoping review and regulatory implications

Liang

Lai

et al. 2021

Chin Med

View full text Add to dashboard Cite

Background The National Medical Products Administration (NMPA) in China has set to advance the regulatory capacity of traditional Chinese medicines (TCMs) with the adoption of regulatory science (RS). However, the priority of actions at the interface of RS and TCMs were yet to be defined. This research aims to identify the priority areas and summarize core actions for advancing RS for traditional medicines in China. Methods A mixed approach of documentary analysis of government policies, regulations and official information about TCMs regulation in China, and a scoping review of literature using 4 databases (PubMed, ScienceDirect, Scopus and CNKI) on major concerns in TCMs regulation was employed. Results Ten priority areas in the development of TCM-related regulatory science in China have been identified, including: (1) modernizing the regulatory system with a holistic approach; (2) advancing the methodology for the quality control of TCMs; (3) fostering the control mechanism of TCMs manufacturing process; (4) improving clinical evaluation of TCMs and leveraging real world data; (5) re-evaluation of TCMs injection; (6) developing evaluation standards for classic TCMs formula; (7) harnessing diverse data to improve pharmacovigilance of TCMs; (8) evaluating the value of integrative medicine in clinical practice with scientific research; (9) advancing the regulatory capacity to encourage innovation in TCMs; and (10) advancing a vision of collaboration for RS development in TCMs. Conclusions RS for TCMs in China encompasses revolution of operational procedures, advancement in science and technology, and cross-disciplinary collaborations. Such experiences could be integrated in the communications among drug regulatory authorities to promote standardized and scientific regulation of traditional medicines.

show abstract

Section: Priority Area 8: Evaluating the Value Of Integrative Medicinmentioning

confidence: 99%